197 related articles for article (PubMed ID: 29963769)
1. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.
Wang Z; Førsund MS; Trope CG; Nesland JM; Holm R; Slipicevic A
Cancer Med; 2018 Aug; 7(8):3955-3964. PubMed ID: 29963769
[TBL] [Abstract][Full Text] [Related]
2. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients.
Magnussen GI; Hellesylt E; Nesland JM; Trope CG; Flørenes VA; Holm R
BMC Cancer; 2013 Jun; 13():288. PubMed ID: 23767999
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship between p53 and phospho-Chk1 (Ser317) protein expression in UVB-induced skin tumors in SKH-1 mice.
Bernard JJ; Lou YR; Peng QY; Li T; Conney AH; Lu YP
Exp Mol Pathol; 2014 Feb; 96(1):126-31. PubMed ID: 24184701
[TBL] [Abstract][Full Text] [Related]
4. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
Sundararajan V; Tan TZ; Lim D; Peng Y; Wengner AM; Ngoi NYL; Jeyasekharan AD; Tan DSP
J Pathol; 2023 Feb; 259(2):194-204. PubMed ID: 36373784
[TBL] [Abstract][Full Text] [Related]
5. 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage.
Kasahara K; Goto H; Enomoto M; Tomono Y; Kiyono T; Inagaki M
EMBO J; 2010 Aug; 29(16):2802-12. PubMed ID: 20639859
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
7. DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism.
Okita N; Minato S; Ohmi E; Tanuma S; Higami Y
FEBS Lett; 2012 Nov; 586(22):3974-9. PubMed ID: 23068608
[TBL] [Abstract][Full Text] [Related]
8. The role of cofilin-l in vulvar squamous cell carcinoma: A marker of carcinogenesis, progression and targeted therapy.
Wu Q; Jiang Y; Cui S; Wang Y; Wu X
Oncol Rep; 2016 May; 35(5):2743-54. PubMed ID: 26936386
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.
Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741
[TBL] [Abstract][Full Text] [Related]
10. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.
Clancy AA; Spaans JN; Weberpals JI
Ann Oncol; 2016 Sep; 27(9):1696-705. PubMed ID: 27329249
[TBL] [Abstract][Full Text] [Related]
11. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
[TBL] [Abstract][Full Text] [Related]
12. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
13. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Wang Z; Trope CG; Flørenes VA; Suo Z; Nesland JM; Holm R
BMC Cancer; 2010 May; 10():233. PubMed ID: 20500813
[TBL] [Abstract][Full Text] [Related]
15. Chk1 phosphorylation at Ser286 and Ser301 occurs with both stalled DNA replication and damage checkpoint stimulation.
Ikegami Y; Goto H; Kiyono T; Enomoto M; Kasahara K; Tomono Y; Tozawa K; Morita A; Kohri K; Inagaki M
Biochem Biophys Res Commun; 2008 Dec; 377(4):1227-31. PubMed ID: 18983824
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.
Wayne J; Brooks T; Massey AJ
Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224
[TBL] [Abstract][Full Text] [Related]
17. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.
Giulia Mantovani ; Fragomeni SM; Inzani F; Fagotti A; Della Corte L; Gentileschi S; Tagliaferri L; Zannoni GF; Scambia G; Garganese G
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1647-1658. PubMed ID: 32335720
[TBL] [Abstract][Full Text] [Related]
19. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma.
Ohashi S; Kikuchi O; Nakai Y; Ida T; Saito T; Kondo Y; Yamamoto Y; Mitani Y; Nguyen Vu TH; Fukuyama K; Tsukihara H; Suzuki N; Muto M
Mol Cancer Ther; 2020 Jun; 19(6):1363-1372. PubMed ID: 32371587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
